Chatelut E - Search Results

1

Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy.

Rubie H, Doz F, Vassal G, Chastagner P, Gentet JC, Urien S, Bastian G, Drouard-Troalen L, Barberi-Heyob M, Catalin J, Chatelut E; Pharmacology Group of the Société Française de Pédiatrie Oncologique. Rubie H, et al. Among authors: chatelut e. Eur J Cancer. 2003 Jul;39(10):1433-8. doi: 10.1016/s0959-8049(03)00314-9. Eur J Cancer. 2003. PMID: 12826047 Clinical Trial.

2

Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.

Chatelut E, Roche H, Plusquellec Y, Peyrille F, De Biasi J, Pujol A, Canal P, Houin G. Chatelut E, et al. J Pharm Sci. 1991 Aug;80(8):730-4. doi: 10.1002/jps.2600800804. J Pharm Sci. 1991. PMID: 1791530

3

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

4

Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).

Canal P, Bugat R, Chatelut E, Pinel MC, Houin G, Plusquellec Y, Carton M. Canal P, et al. Among authors: chatelut e. Eur J Cancer Clin Oncol. 1989 May;25(5):815-20. doi: 10.1016/0277-5379(89)90126-0. Eur J Cancer Clin Oncol. 1989. PMID: 2737218

5

[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].

Lavit M, Chevreau C, Chatelut E, De Fenin V, Lochon I, Houin G, Bugat R, Canal P. Lavit M, et al. Among authors: chatelut e. Bull Cancer. 1995 Aug;82(8):660-4. Bull Cancer. 1995. PMID: 7492822 French.

6

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R. Chatelut E, et al. J Natl Cancer Inst. 1995 Apr 19;87(8):573-80. doi: 10.1093/jnci/87.8.573. J Natl Cancer Inst. 1995. PMID: 7752255

7

A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

Chatelut E, Chevreau C, Brunner V, Martinez M, Houin G, Bugat R, Canal P. Chatelut E, et al. Cancer Chemother Pharmacol. 1995;35(5):391-6. doi: 10.1007/s002800050252. Cancer Chemother Pharmacol. 1995. PMID: 7850920 Clinical Trial.

8

[Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors].

Bachaud JM, Albin N, Gay C, Chatelut E, Benchalal M, David JM, Boneu A, Serrano E, Canal P, Daly-Schveitzer N. Bachaud JM, et al. Among authors: chatelut e. Bull Cancer. 1994 Mar;81(3):212-8. Bull Cancer. 1994. PMID: 7894129 French.

9

Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency.

Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G, Canal P. Chatelut E, et al. Nephron. 1994;66(2):157-61. doi: 10.1159/000187794. Nephron. 1994. PMID: 8139735

10

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.

Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G. Attal M, et al. Among authors: chatelut e. J Clin Oncol. 1994 Jan;12(1):141-8. doi: 10.1200/JCO.1994.12.1.141. J Clin Oncol. 1994. PMID: 8270970 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters